Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.
Hontecillas-Prieto L, García-Domínguez DJ, Palazón-Carrión N, Martín García-Sancho A, Nogales-Fernández E, Jiménez-Cortegana C, Sánchez-León ML, Silva-Romeiro S, Flores-Campos R, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Salar-Silvestre A, Rodríguez-Abreu D, Gálvez-Carvajal L, Labrador J, Guirado-Risueño M, Provencio-Pulla M, Sánchez-Beato M, Marylene L, Álvaro-Naranjo T, Casanova-Espinosa M, Rueda-Domínguez A, Sánchez-Margalet V, de la Cruz-Merino L. Hontecillas-Prieto L, et al. Among authors: nogales fernandez e. Front Immunol. 2024 Feb 26;15:1293931. doi: 10.3389/fimmu.2024.1293931. eCollection 2024. Front Immunol. 2024. PMID: 38469299 Free PMC article. Clinical Trial.
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.
Palazón-Carrión N, Martín García-Sancho A, Nogales-Fernández E, Jiménez-Cortegana C, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Salar-Silvestre A, Rodríguez-Abreu D, Gálvez-Carvajal L, Labrador J, Guirado-Risueño M, García-Domínguez DJ, Hontecillas-Prieto L, Espejo-García P, Fernández-Román I, Provencio-Pulla M, Sánchez-Beato M, Navarro M, Marylene L, Álvaro-Naranjo T, Casanova-Espinosa M, Sánchez-Margalet V, Rueda-Domínguez A, de la Cruz-Merino L. Palazón-Carrión N, et al. Among authors: nogales fernandez e. Clin Cancer Res. 2022 Sep 1;28(17):3658-3668. doi: 10.1158/1078-0432.CCR-22-0588. Clin Cancer Res. 2022. PMID: 35727601 Free PMC article. Clinical Trial.
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Free PMC article. Clinical Trial.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Cortés J, et al. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. N Engl J Med. 2022. PMID: 35320644 Clinical Trial.
Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial.
Jiménez-Cortegana C, Sánchez-Martínez PM, Palazón-Carrión N, Nogales-Fernández E, Henao-Carrasco F, Martín García-Sancho A, Rueda A, Provencio M, de la Cruz-Merino L, Sánchez-Margalet V. Jiménez-Cortegana C, et al. Among authors: nogales fernandez e. Cancers (Basel). 2021 Sep 15;13(18):4622. doi: 10.3390/cancers13184622. Cancers (Basel). 2021. PMID: 34572849 Free PMC article.
Publisher Correction: Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer.
Palazón-Carrión N, Jiménez-Cortegana C, Sánchez-León ML, Henao-Carrasco F, Nogales-Fernández E, Chiesa M, Caballero R, Rojo F, Nieto-García MA, Sánchez-Margalet V, de la Cruz-Merino L; Spanish Breast Cancer Group (GEICAM) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA). Palazón-Carrión N, et al. Among authors: nogales fernandez e. Sci Rep. 2021 Aug 30;11(1):17639. doi: 10.1038/s41598-021-96901-8. Sci Rep. 2021. PMID: 34462490 Free PMC article. No abstract available.
Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer.
Palazón-Carrión N, Jiménez-Cortegana C, Sánchez-León ML, Henao-Carrasco F, Nogales-Fernández E, Chiesa M, Caballero R, Rojo F, Nieto-García MA, Sánchez-Margalet V, de la Cruz-Merino L; Spanish Breast Cancer Group (GEICAM) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA). Palazón-Carrión N, et al. Among authors: nogales fernandez e. Sci Rep. 2021 Jul 13;11(1):14426. doi: 10.1038/s41598-021-93838-w. Sci Rep. 2021. PMID: 34257359 Free PMC article.
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial.
Jiménez-Cortegana C, Palazón-Carrión N, Martin Garcia-Sancho A, Nogales-Fernandez E, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Rueda Dominguez A, Casanova-Espinosa M, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Labrador J, Salar-Silvestre A, Rodriguez-Abreu D, Galvez-Carvajal L, Provencio M, Sánchez-Beato M, Guirado-Risueño M, Espejo-García P, Lejeune M, Álvaro T, Sánchez-Margalet V, de la Cruz-Merino L; Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA); Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA); Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA). Jiménez-Cortegana C, et al. Among authors: nogales fernandez e. J Immunother Cancer. 2021 Jun;9(6):e002323. doi: 10.1136/jitc-2020-002323. J Immunother Cancer. 2021. PMID: 34158317 Free PMC article.
Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice.
Pérez-Ruiz E, Jiménez-Castro J, Berciano-Guerrero MA, Valdivia J, Estalella-Mendoza S, Toscano F, Rodriguez de la Borbolla Artacho M, Garrido-Siles M, Martínez-Bautista MJ, Villatoro Roldan R, Rivas-Ruiz F, Nogales-Fernández E, Morales C, Pérez-Valderrama B, De la Cruz-Merino L, Rueda A. Pérez-Ruiz E, et al. Among authors: nogales fernandez e. Clin Transl Oncol. 2020 Oct;22(10):1778-1785. doi: 10.1007/s12094-020-02315-9. Epub 2020 Feb 24. Clin Transl Oncol. 2020. PMID: 32096143
Circulating regulatory T cells from breast cancer patients in response to neoadjuvant chemotherapy.
Sánchez-Margalet V, Barco-Sánchez A, Vilariño-García T, Jiménez-Cortegana C, Pérez-Pérez A, Henao-Carrasco F, Virizuela-Echaburu JA, Nogales-Fernández E, Álamo-de la Gala MC, Lobo-Acosta MA, Palazón-Carrión N, Nieto A, de la Cruz-Merino L. Sánchez-Margalet V, et al. Among authors: nogales fernandez e. Transl Cancer Res. 2019 Feb;8(1):59-65. doi: 10.21037/tcr.2018.12.30. Transl Cancer Res. 2019. PMID: 35116734 Free PMC article.
14 results